| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.7K | 31.5% | 37.7% |
| Total Income | 1.7K | 31.5% | 37.7% |
| Expenditure | 976.14 | 0.5% | 42.5% |
| PBT | 751.51 | 118.7% | 34.7% |
| Net Profit | 585.61 | 93.1% | 44.6% |
| OPM | 41.69% | 18.03pp | 1.94pp |
| NPM | 34.98% | 11.15pp | 1.66pp |
| EPS | 2.92 | 92.1% | 39.7% |
Incyte Reports Q2 2026 Total Revenue of $1.67 Billion, Up 38% Year-over-Year
28 Jul 2026 · 28 Jul, 4:37 pm
Summary
Incyte Corporation reported robust financial results for the second quarter of 2026, with total revenue climbing 38% year-over-year to $1.67 billion and total net sales increasing 40% to $1.49 billion. This growth was significantly bolstered by a 173% rise in Opzelura net sales to $450 million, which included a $246 million one-time non-cash benefit from a CMS agreement. Jakafi net sales also contributed positively, growing 7% to $817 million, while the Hematology and Oncology portfolio saw a 69% increase in net sales. The company has raised its full-year 2026 total net sales guidance, reflecting continued strong performance and strategic business developments.
Key Highlights
- 1
Total revenue for the second quarter of 2026 reached $1.67 billion, marking a significant 38% increase compared to the second quarter of 2025.
- 2
Total net sales grew by 40% year-over-year to $1.49 billion in Q2 2026, driven by increased demand across marketed products and a one-time non-cash benefit.
- 3
Opzelura net sales surged by 173% to $450 million in the second quarter of 2026, including a $246 million one-time non-cash benefit from a CMS agreement.
- 4
Jakafi net sales increased by 7% to $817 million in Q2 2026, primarily due to a 9% increase in paid demand across all indications.
- 5
The Hematology and Oncology portfolio recorded net sales of $222 million, representing a 69% increase compared to the prior year period.
- 6
Incyte raised its full-year 2026 total net sales guidance to a range of $5,130 million to $5,260 million, reflecting strong product performance and the CMS agreement impact.
- 7
Cash, cash equivalents, and marketable securities stood at $4.5 billion as of June 30, 2026, up from $3.6 billion at the end of 2025.
Management Comments
Bill Meury
Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development. Every marketed product contributed to growth, reflecting the strength of our commercial portfolio and execution. We also recently strengthened our Hematology franchise through the acquisition of latarcibart, a potentially transformative medicine for von Willebrand disease currently in Phase 3 development. With ten data readouts expected in the second half of 2026, alongside product launches through early next year, we are well positioned for our next phase of growth.
Informational and educational content only. Not investment advice.